PMID- 36839715
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230301
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 15
IP  - 2
DP  - 2023 Jan 24
TI  - Nanosized Drug Delivery Systems to Fight Tuberculosis.
LID - 10.3390/pharmaceutics15020393 [doi]
LID - 393
AB  - Tuberculosis (TB) is currently the second deadliest infectious disease. Existing 
      antitubercular therapies are long, complex, and have severe side effects that 
      result in low patient compliance. In this context, nanosized drug delivery 
      systems (DDSs) have the potential to optimize the treatment's efficiency while 
      reducing its toxicity. Hundreds of publications illustrate the growing interest 
      in this field. In this review, the main challenges related to the use of drug 
      nanocarriers to fight TB are overviewed. Relevant publications regarding DDSs for 
      the treatment of TB are classified according to the encapsulated drugs, from 
      first-line to second-line drugs. The physicochemical and biological properties of 
      the investigated formulations are listed. DDSs could simultaneously (i) optimize 
      the therapy's antibacterial effects; (ii) reduce the doses; (iii) reduce the 
      posology; (iv) diminish the toxicity; and as a global result, (v) mitigate the 
      emergence of resistant strains. Moreover, we highlight that host-directed therapy 
      using nanoparticles (NPs) is a recent promising trend. Although the research on 
      nanosized DDSs for TB treatment is expanding, clinical applications have yet to 
      be developed. Most studies are only dedicated to the development of new 
      formulations, without the in vivo proof of concept. In the near future, it is 
      expected that NPs prepared by "green" scalable methods, with intrinsic 
      antibacterial properties and capable of co-encapsulating synergistic drugs, may 
      find applications to fight TB.
FAU - Bourguignon, Tom
AU  - Bourguignon T
AD  - Institut des Sciences Moleculaires d'Orsay, Universite Paris-Saclay, CNRS, 91405 
      Orsay, France.
FAU - Godinez-Leon, Jesus Alfredo
AU  - Godinez-Leon JA
AUID- ORCID: 0000-0001-9498-4693
AD  - Institut des Sciences Moleculaires d'Orsay, Universite Paris-Saclay, CNRS, 91405 
      Orsay, France.
FAU - Gref, Ruxandra
AU  - Gref R
AUID- ORCID: 0000-0002-7869-0908
AD  - Institut des Sciences Moleculaires d'Orsay, Universite Paris-Saclay, CNRS, 91405 
      Orsay, France.
LA  - eng
GR  - ANR-10-LABX-0035/Agence Nationale de la Recherche/
GR  - ANR-20-CE19-002/Agence Nationale de la Recherche/
GR  - MITI/French National Centre for Scientific Research/
PT  - Journal Article
PT  - Review
DEP - 20230124
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC9964171
OTO - NOTNLM
OT  - antitubercular treatment
OT  - biodegradable polymers
OT  - drug delivery systems
OT  - drug nanocarriers
OT  - host-directed therapy
OT  - nanoparticles
OT  - physicochemical characterization
OT  - targeted delivery
OT  - tuberculosis
COIS- The authors declare no conflict of interest.
EDAT- 2023/02/26 06:00
MHDA- 2023/02/26 06:01
PMCR- 2023/01/24
CRDT- 2023/02/25 04:16
PHST- 2022/12/30 00:00 [received]
PHST- 2023/01/17 00:00 [revised]
PHST- 2023/01/20 00:00 [accepted]
PHST- 2023/02/25 04:16 [entrez]
PHST- 2023/02/26 06:00 [pubmed]
PHST- 2023/02/26 06:01 [medline]
PHST- 2023/01/24 00:00 [pmc-release]
AID - pharmaceutics15020393 [pii]
AID - pharmaceutics-15-00393 [pii]
AID - 10.3390/pharmaceutics15020393 [doi]
PST - epublish
SO  - Pharmaceutics. 2023 Jan 24;15(2):393. doi: 10.3390/pharmaceutics15020393.